Courier Capital LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,862 shares of the company’s stock after selling 1,454 shares during the period. Johnson & Johnson accounts for about 1.4% of Courier Capital LLC’s portfolio, making the stock its 13th largest position. Courier Capital LLC’s holdings in Johnson & Johnson were worth $7,954,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Feltz Wealth PLAN Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth approximately $221,000. Whitnell & Co. raised its position in shares of Johnson & Johnson by 1.2% in the first quarter. Whitnell & Co. now owns 27,764 shares of the company’s stock worth $3,458,000 after buying an additional 338 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Johnson & Johnson by 2.6% in the first quarter. Nisa Investment Advisors LLC now owns 998,060 shares of the company’s stock worth $124,308,000 after buying an additional 25,020 shares during the period. Barometer Capital Management Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth approximately $249,000. Finally, Coastline Trust Co raised its position in shares of Johnson & Johnson by 1.0% in the first quarter. Coastline Trust Co now owns 51,670 shares of the company’s stock worth $6,435,000 after buying an additional 535 shares during the period. 66.06% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE JNJ) traded down 0.44% during trading on Tuesday, hitting $132.27. 5,514,761 shares of the stock traded hands. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The company’s 50 day moving average is $133.35 and its 200 day moving average is $125.64. The firm has a market cap of $356.31 billion, a PE ratio of 22.38 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the prior year, the business earned $1.74 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio is 56.76%.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/courier-capital-llc-sells-1454-shares-of-johnson-johnson-jnj-updated-updated-updated/1194622.html.
Several equities analysts recently issued reports on the stock. Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target on the stock. in a report on Friday, July 21st. Finally, BTIG Research lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target on the stock. in a report on Friday, July 21st. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $133.72.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.